It was a relatively quiet day on the news front outside of the hep-C space where there as some news on both VRTX and GILD. Not much happening in the afternoon, so wrapping it up a little early. 1. VRTX announced that the FDA put a clinical hold on their all oral trial using VX-135. […]
July 25- EOD
We had a lot of large cap biotech news in terms of the earnings and I wanted to focus on two of them as both had clean beats but also gave some investors pause: CELG and BIIB. 1. BIIB absolutely blew out BG-12 sales. The sell side consensus was $70M and the buyside whisper was […]
July 24- EOD
The news du jour today was SRPT and I want to focus today’s note entirely on it because there is a lot to talk about. In addition, I want to focus on the bearish aspects to the story as I think the bullish case has been fairly well laid out. I would certainly not interpret […]
July 23- EOD
We still seem to be in a period of low news flow in terms of biotech stocks, which is fine as it gives me a chance to catch up on some longer term stories. In particular, I want to spend some time talking about ONTX as it should start trading Thursday and it is an […]
July 22- EOD
It is more of the same in that the market is a little quiet on news. I expected that there would be something interesting to talk about today but not so much. That being said there are a couple of items that I think might be important to note. 1. There has been a lot […]
July 19- EOD
Really seemed like a quiet summer day to end the week. Not much to talk about but a couple of follow up notes from earlier discussions. 1. To continue from my MYGN notes from yesterday, it was confirmed from LH that they will be in the BRCA market. This just builds on the bear case […]
July 18- EOD
Not a ton of news today, so this will be a little bit of a short update but some company specific news with CELG. Outside of that there was the IPO mania that might very well be peaking. I am not convinced that we are in a complete bubble simply because everyone is calling it […]
July 17- EOD
Well, we finally had a biotech merger but not any of the ones we expected. Outside of the small cap buyout, there was not a lot new today. 1. SPPI bought TLON this morning. What is really odd was that I almost wrote about SPPI yesterday but decided against it. When I was thinking about […]
July 16- EOD
Seemed like a slow news day as the markets pulled back to consolidate some of the recent moves. Biotechs were not immune to the move, although some clearly performed better than others. 1. EPZM has shown incredible strength since the IPO. While I like this company’s technology and would like to own some shares, it […]
July 15- EOD
Well, there was not a lot of news out there in biotech land but oddly there is a lot I want to talk about and will work through it over the next couple of days. 1. ARIA Iclusig prescriptions came in weak again with new prescriptions down 26% and only a 9% gain in continuing […]
July 12- EOD
There have been a couple days of biotech buying, especially it seems in the small cap antibiotic space. Outside of the general performance, there has been some significant news. All in all a couple of interesting days. 1. I was tempted to write a quick update yesterday about the CELG MM-020 results but did not […]
July 10- EOD
Got some interesting news today, which makes this a little more exciting but still not a huge news day (the theme for the week). There will not by a note tomorrow as I need to pick my family up at the airport in the morning and have a doctor appointment in the afternoon. Of course, […]
July 9- EOD
Another slow day, although there was some more interesting news. Biotechs continued to underperform the broader market and I suspect that will be a trend for the next couple of days as the move last week is digested. This is going out a little early because I have to head out before the end of […]
July 8- EOD
Perhaps we were spoiled last week with the ONXX news but this week seems to be getting off to a slow start. There were some decent sized moves in biotech but in terms of news flow it was a little light. We might be in for a little bit of a breather in terms of […]
July 2- EOD–> Midday edition
I wanted to follow up on the discussion of yesterday less with an analysis of the potential dance partners for ONXX but more in terms of where do we go from here. Obviously the speculation in mid and small caps space is who will be next. This list could encompass just about every company but […]
July 1- EOD
Today was the fallout of the AMGN bid for ONXX. There are a couple of aspects of it that I want to touch on and go a little further than my article this morning. 1. In my article I tried to cover the companies that I thought had the most compelling reasons to be interested […]
June 28- EOD
Not much of a lot of new today but there were some interesting tidbits. 1. BIIB spiked higher today on the back of SNY news. The EMA granted Aubagio exclusivity and traders immediately wanted to tie this into the debate over BG12 exclusivity in the EU. I am not sure that this is anything more […]
June 27- EOD
I thought today would be a much better day in the market for biotechs and they looked strong early but did not seem to have any real follow through. Not that it was a bad day; rather, it seemed to show more strength early. Still some stock specific stories to talk about. 1. CELG signed […]
June 26- EOD
Generally it was a good bounce back day for a lot of biotechs, although there were some pockets of underperformance. That being said, this is a positive day but the real test will be when these stock get to their 50-day moving average and whether they can decisively move back above them. Until then I […]
June 25- EOD
It was an odd day in the market as it was strong but many biotechs appeared weak. I am going to focus exclusively today on SGEN as we got more details and I have been digging into the weeds to try and get a handle on what this means. So there were more details on […]
